Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study

Thomas Cluzeau, Cecile Favreau, Maxence Bourgoin, Geoffroy Venton, Raphaelle Fanciullino, Melanie Boucher, Caroline Fileni, Sami Benachour, Michael Loschi, Berengere Dadone-Montaudie, Patrick Auberger, Arnaud Jacquel, Guillaume Robert

Blood (2025) 146 (Supplement 1): 5250.

https://doi.org/10.1182/blood-2025-5250

Published: 2025

Journal Articles

Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Sylvain Garciaz, Rémy Castellano, Arnaud Jacquel, Arnaud Guille, Maxence Bourgoin, Camille Montersino, José Adélaïde, Patrick Auberger, Daniel Birnbaum, Marie Anne Hospital, Yves Collette, Norbert Vey

Blood (2024) 144 (Supplement 1): 1378.

https://doi.org/10.1182/blood-2024-207352

Published: 2024